You searched for "Prostate cancer"
MRI screening for prostate cancer: a step towards a ‘prostagram’
The UK National Screening Committee has been calling for further research into alternative screening tests for prostate cancer. The committee decided against prostate cancer screening using prostate specific antigen (PSA) testing on the basis that “PSA is still a poor...
Active surveillance for intermediate-risk prostate cancer
In this review, Klotz and Dall’Era summarise available data from the Toronto, UCSF, ERSPC, PASS and Royal Marsden active surveillance cohorts, looking specifically at outcomes of patients classed as intermediate risk. Cancer specific survival in men managed initially with active...
Abiraterone acetate in men with castration-resistant prostate cancer
With emerging results from the Stampede and Latitude studies, abiraterone has taken the forefront in the management of metastatic prostate cancer while researchers try to identify the ideal timing for administration. It is a potent inhibitor of CYP17 which results...
Is AS in SRM more convincing than in prostate cancer?
This article reviews active surveillance (AS) in the management of small renal masses (SRM), the role of renal tumour biopsy (RTB), patient selection, tumour growth kinetics, and outcomes. SRMs which are defined as masses ≤4 cm in diameter and enhance...
MSKCC prostate cancer screening guidelines – is it the way forward?
The Memorial Sloan Kettering Cancer Center (MSKCC) developed prostate cancer screening recommendations first in 2011 as a response to three limitations of previous screening guidelines: insufficient evidence base, failure to link screening with treatment, and lack of risk stratification. To...
Patient-reported outcomes after prostate cancer treatment
This study used the survivorship (LIVESTRONG) care plan tool to identify patient-reported toxicities that occurred following treatment for prostate cancer. All patients had undergone treatments, which were considered to have similar oncological endpoints. The tool asked patients questions with regard...
The EP2 receptor – a novel target for prostate cancer?
This basic science paper sets out to evaluate the effects that celecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor, have on prostate cancer cell lines and evaluated the mechanisms behind these effects. COX-2 induces the production of prostaglandins, which promote cell proliferation...
Indication to pelvic lymph nodes dissection for prostate cancer
This paper explored the role of multiparametric MRI (mpMRI) in predicting the likelihood of lymph node invasion in patients with a risk of <5% according to the Briganti nomogram. Three hundred and ten patients who underwent a preoperative mpMRI and...
Urethral stenosis after radiation therapy for prostate cancer
One of the most common causes of bladder outflow obstruction in post radiotherapy (RT) cases is urethral stenosis. These cases are miserable and moribund with poor flow rates, incomplete bladder emptying, recurrent urinary tract infections and haematuria. The reported incidence...
Cost effectiveness of prostate cancer screening in Europe
Prostate cancer (PCa) stands as the most prevalent cancer and the third leading cause of cancer-related deaths among men in Europe. According to data from the European Commission, in 2020, PCa represented a staggering 23.2% of all new cancer cases...
